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Abstract A preliminary model has been calculated for the
activating interaction of the interleukin 1 receptor (IL-1R)
accessory protein IL-1RAcP with the ligand/receptor complex
IL-1L/IL-1RI. First, IL-1RAcP was modeled on the crystal
structure of IL-1RI bound to IL-1L. Then, the IL-1RAcP model
was docked using specific programs to the crystal structure of the
IL-1L/IL-1RI complex. Two types of models were predicted, with
comparable probability. Experimental data obtained with the use
of IL-1L peptides and antibodies, and with mutated IL-1L
proteins, support the BACK model, in which IL-1RAcP
establishes contacts with the back of IL-1RI wrapped around
IL-1L. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The cytokine interleukin 1 (IL-1) induces multiple physio-
logical responses to in£ammation, infection, and tissue dam-
age [1]. Its potent defense activity requires a tight control, to
avoid unwanted pathological derangements [1]. Initiation of
cell activation occurs upon binding of agonist ligands (IL-1K
or IL-1L) to a speci¢c membrane receptor, the transmembrane
glycoprotein of the immunoglobulin (Ig) superfamily IL-1RI
[2]. Conversely, binding of the antagonist ligand IL-1ra does
not initiate signaling. The mode of agonist vs. antagonist in-
teraction has been clari¢ed after crystallization and structure
resolution of IL-1RI complexed with IL-1L [3] and IL-1ra [4].
From these studies, it appears that the three Ig-like domains
of IL-1RI wrap around agonist IL-1L, thanks to the £exible
areas between the Ig-like domains. In the antagonist interac-
tion with IL-1ra, only the ¢rst two receptor domains establish
contact with the ligand, while the third domain remains free.
Binding of IL-1 to IL-1RI is not su⁄cient for initiation of cell
activation. A second chain, the accessory protein IL-1RAcP,
is necessary for IL-1-dependent signaling [5^7]. This chain,
structurally very similar to IL-1RI, does not bind IL-1 but
interacts with the complex IL-1/IL-1RI, possibly by establish-
ing contact with the third domain of the receptor [8,9]. The
approach of the cytosolic segments of IL-1RI and IL-1RAcP
initiates signaling. On the other hand, IL-1RAcP cannot bind
to the antagonist complex IL-1ra/IL-1RI and activation does
not occur [5]. The mode of interaction between IL-1RAcP and
the activating complex IL-1/IL-1RI is still elusive, as the struc-
ture of IL-1RAcP is unknown. This study was therefore
undertaken in order to predict a model for the trimeric acti-
vating interaction IL-1L/IL-1RI/IL-1RAcP. Identi¢cation of
areas involved in the activating interaction will open new pos-
sibilities for targeted strategies of inhibition to be used in
IL-1-dependent chronic in£ammatory or autoimmune pathol-
ogies.
2. Materials and methods
2.1. Computational methods
Modeling of the IL-1RAcP was performed using the IL-1RI protein
(1ITB, PDB protein code, 0.25 nm resolution) as template. Sequence
alignment was performed with CLUSTALW [10] and LALIGN
(www.ch.embnet.org/software/LALIGN_FORM.html). Secondary
structure prediction was performed with a neural network predictor
implemented in-house [11]. The 3D model was computed with the
program MODELLER [12] and its quality checked with PRO-
CHECK [13]. The Autodock suite of programs was used to determine
the interaction between IL-1RAcP and the IL-1L/IL-1RI complex
[14]. The ¢nal con¢guration of the complex was selected on the basis
of minimal energy values. Models were visualized with RASMOL
[15].
2.2. Antibody production
The synthetic peptide LKDDKPTLQ (sequence 73^81 of human
IL-1L) was conjugated to keyhole limpet hemocyanin, and inoculated
repeatedly with adjuvants in New Zealand White rabbits (for produc-
tion of polyclonal antibodies) and in BALB/c mice (for generation of
monoclonal antibodies), as described [16,17]. Rabbit serum IgGs were
puri¢ed by protein G. For monoclonal antibody generation, popliteal
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lymph node cells were fused with murine myeloma cells P3X63-
Ag8.653, antibody-producing hybridomas were cloned and subcloned
and antibodies screened for recognition of IL-1L in radioimmunoas-
say (RIA) [17]. Puri¢ed polyclonal IgG (Vhp19) and the selected
monoclonal antibody (Vhp19G; IgG3) recognized both the 73^81
peptide and human recombinant IL-1L in RIA, and natural IL-1L
in immuno£uorescence on lipopolysaccharide-stimulated monocytes,
but did not bind IL-1L in Western blot. Anti-IL-1L antibodies BRhC3
and BRhD2 [18,19] were used as controls.
2.3. Binding assays
The e¡ect of antibodies on IL-1L binding to IL-1RI was assessed on
the murine T cell lines EL4-6.1 or D10.G4.1 [20]. Brie£y, cells were
exposed to 125I-labeled IL-1L (0.4 nM), which had been pre-incubated
in the absence or in the presence of antibodies overnight at 4‡C [18].
After 90 min at room temperature, cell-bound radioactivity was
counted in a Q-counter. Non-speci¢c binding was determined in the
presence of a 1000-fold excess of unlabeled IL-1L.
2.4. Biological assays
The e¡ect of antibodies on the biological activity of IL-1L was
assessed in three di¡erent biological assays, i.e. the IL-1L-dependent
proliferation of murine thymocytes (lymphocyte-activating factor
(LAF) assay) [21,22] and of the murine Th2 cell line D10.G4.1
(D10 assay) [22], and the IL-1L-stimulated production of prostaglan-
din E2 (PGE2) by human F7100 ¢broblasts (PGE2 assay) [21]. Brie£y,
cells were exposed to IL-1L (0.01^1 ng/ml in the LAF assay; 2^20 pg/
ml in the D10 assay; 0.02^0.5 ng/ml in the PGE2 assay) in the absence
or in the presence of antibodies. After incubation at 37‡C for 2^3
days, supernatants were collected for PGE2 determination (by RIA;
DuPont NEN, Boston, MA, USA) or cells pulsed with [3H]thymidine
for 18 h for determination of proliferation.
3. Results and discussion
A model of IL-1RAcP was calculated on the basis of align-
ment of primary sequence and secondary structure with IL-
1RI, and then modeled on the crystal structure of IL-1RI
bound to IL-1L [3]. Two other IL-1RI structures were avail-
able, i.e. that of the complex with the antagonist IL-1ra [4]
and that of the complex with the 21 amino acid long antag-
onist peptide AF10847 [23]. Both interactions are abortive in
terms of cell activation, i.e. do not allow interaction with the
IL-1RAcP and initiation of signaling. Their IL-1RI structures
were thus not considered high probability templates for the
IL-1RAcP model. The IL-1RAcP model structure is shown in
Fig. 1A.
Docking of IL-1RAcP to the crystal structure of IL-1RI
bound to IL-1L was attempted with Autodock programs. As
a control, the same attempt was made on the crystal structure
of IL-1RI bound to IL-1ra and, as expected, no interaction
could be calculated (data not shown). Two possible types of
IL-1L/IL-1RI/IL-1RAcP interaction were calculated. The ¢rst
type of interaction (FRONT model) places the IL-1RAcP
chain across the IL-1L/IL-1RI complex, partially covering
the area of IL-1L not involved in receptor binding (Fig. 1B).
Conversely, the second type of interaction (BACK model)
places IL-1RAcP across the back of the complex, engaging
part of IL-1RI (in particular the second and third Ig-like
domains) and parts of IL-1L along the border of interaction
with IL-1RI (Fig. 1C).
To discriminate between the two models, an experimental
approach was designed. This implies, based on the model
structures, the identi¢cation of areas of IL-1L in close prox-
imity to IL-1RAcP in one model and completely detached
from IL-1RAcP in the other. One such area was identi¢ed
as the stretch in position 73^81 in the mature IL-1L sequence
(LKDDKPTLQ). This area is in close vicinity to residues of
IL-1RAcP in the FRONT model (average of 3.5 Aî ; see cyan
area in Fig. 1B), whereas it is located at over 20 Aî from the
closest IL-1RAcP residues in the BACK model (see cyan area
in Fig. 1C). A synthetic peptide corresponding to the sequence
73^81 was synthesized and used to immunize mice and rab-
bits, to generate antibodies of pre-determined speci¢city.
These antibodies, dubbed Vhp19, recognize speci¢cally and
with a signi¢cant a⁄nity both the immunizing peptide and
the entire IL-1L (Table 1). The ability of Vhp19 to interfere
with IL-1L binding to IL-1RI was assessed and compared to
inhibition of IL-1L biological activity. As shown in Table 1,
Vhp19 did not a¡ect the capacity of IL-1L to interact with IL-
1RI. This is in agreement with the information gathered from
the crystal structure of the IL-1L/IL-1RI interaction, where it
is clear that IL-1L area 73^81 is not involved in receptor
binding (see Fig. 1B,C). If the area recognized by Vhp19 is
involved in the interaction with IL-1RAcP (as in the FRONT
model), Vhp19 would be expected to inhibit IL-1L biological
e¡ects. However, as shown in Table 1, Vhp19 is completely
unable to inhibit either IL-1L-induced lymphocyte prolifera-
tion (LAF and D10 assays) or IL-1L-induced production of
Table 1
E¡ect of antibodies of pre-determined speci¢city on IL-1L functions
Antibodya IL-1L epitope
recognized
Recognition of IL-1L
A⁄nity in RIA (Ka,
l/mol)b
Percent inhibition of
binding to IL-1RcI
Percent inhibition of activity in
LAF assayc D10 assayc PGE2 assayc
Unrelated none n.d. 6.5 þ 2.0 34.9 þ 3.8 313.2 þ 2.9 321.3 þ 3.5
Vhp19 73^81 4.6U108 35.6 þ 4.2 35.3 þ 3.3 32.4 þ 4.3 310.6 þ 3.9
BRhC3 17^31 5.8U108 81.1 þ 4.3* 78.0 þ 3.1* 74.8 þ 6.7* 69.9 þ 3.3*
BRhD2 61^70 1.0U109 3.4 þ 0.6 68.6 þ 3.8* 81.5 þ 4.3* n.t.
n.d., not detectable; n.t., not tested; not signi¢cant vs. control without antibodies; *P6 0.01 vs. control without antibodies.
aUnrelated antibodies included monoclonal antibodies and polyclonal rabbit Ig to K-vimentin and to human growth hormone and normal rab-
bit Ig.
bOn immobilized IL-1L. Controls with unrelated proteins (IL-1K, bovine serum albumin) or peptides (other IL-1L peptides) yielded no reactiv-
ity.
cMean þ S.E.M. of data obtained with antibody concentrations ranging from 1 to 100 Wg/ml (IL-1RI, LAF and D10) or from 50 to 250 Wg/ml
(PGE2) in 3^37 separate determinations. No inhibition of IL-1K was detected. Mean control 100% values (in the absence of antibodies) were:
for receptor binding 11 776 þ 38 (cpm of speci¢c IL-1L binding), for LAF assay 30 069 þ 5406 (cpm of speci¢c IL-1L-induced proliferation), for
D10 assay 40 409 þ 6687 (cpm of speci¢c IL-1L-induced proliferation), for PGE2 assay 139.8 þ 35.6 (speci¢c IL-1L-induced ng PGE2/mg cell pro-
tein).
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PGE2 in ¢broblasts (PGE2 assay). To support these data, a
series of mutations in area 74^80 did not a¡ect IL-1L binding
to IL-1RI or biological activity [24]. In addition, the synthetic
peptide corresponding to area 73^81 could not inhibit IL-1RI
binding or biological activity of IL-1L (unpublished). As a
control, an antibody to an area involved in IL-1RI binding
(BRhC3, recognizing an epitope within region 27^31) e¡ec-
tively inhibited both binding and biological activities of IL-
1L, whereas unrelated antibodies (to K-vimentin or to human
growth hormone) were completely inactive. Eventually, anoth-
er antibody (BRhD2, recognizing an epitope within the IL-1L
sequence 61^70) could not inhibit receptor binding but signi¢-
cantly decreased the biological e¡ects of IL-1L, thus possibly
interfering with recruitment of IL-1RAcP to the IL-1L/IL-1RI
complex. Thus, although it cannot discriminate between the
two models, IL-1L area 61^70 looks very important in the
interaction with IL-1RAcP [19]. Indeed, the double mutation
of lysine residues in positions 63/65 to serine causes a signi¢-
cant impairment of biological activity without a¡ecting bind-
ing to IL-1RI [27,28] (Table 2).
To gather further information which could allow discrim-
ination between the two models, a literature survey was per-
formed to identify IL-1L muteins with discrete e¡ects on
receptor binding and biological activity [25]. Table 2 summa-
rizes the few described mutations of amino acids on the ex-
ternal surface of the IL-1L molecule (internal mutations have
been excluded) which do not signi¢cantly a¡ect binding to
IL-1RI but profoundly impair biological activity (i.e. possibly
involved in the interaction with IL-1RAcP). Calculations
of distance between these IL-1L mutations and IL-1RAcP
show that in the majority of instances these positions are
much closer to IL-1RAcP in the BACK model than in
the FRONT model. As already mentioned, one exception
is the mutation K63S, which is in close proximity to IL-
1RAcP in both models and therefore does not allow discrim-
ination.
A series of other data are available, mainly obtained with
antibodies raised against synthetic peptides, which help in the
identi¢cation of interaction areas of IL-1L [24], IL-1RI [32]
and IL-1RAcP [8]. None of these data provide a clear indica-
tion to support one of the two proposed models. However, the
experimental evidence is that IL-1RAcP interacts with IL-1R
(bound to agonist IL-1L) through its second and/or third do-
main [8,9]. Since IL-1RAcP is unable to directly bind IL-1L
with su⁄cient a⁄nity [5], it could be hypothesized that com-
plex formation between IL-1L and IL-1RI leads to the crea-
tion of novel surface areas which include residues from both
IL-1L and IL-1RI and which can be bound with high a⁄nity
by IL-1RAcP.
This study therefore proposes a preliminary model to de-
scribe the activating interaction of IL-1RAcP with the com-
plex IL-1L/IL-1RI. The model hypothesizes that IL-1RAcP
establishes contacts with the back of IL-1RI wrapped around
IL-1L and with some parts of IL-1L in the proximity of con-
tact areas with IL-1RI. A ¢rst validation of the model comes
from experimental data obtained with synthetic peptides and
speci¢c antibodies. After further re¢nement and deeper exper-
imental validation, the model may become the structural basis
Fig. 1. Model of IL-1RAcP and of the complex IL-1L/IL-1RI/IL-1RAcP. The molecular model of IL-1RAcP (red) is depicted in A. The ¢rst
and second Ig-like domains on the top appear as a compact structure, whereas the third domain, at the bottom, is clearly distinct. B represents
the hypothetical FRONT model of interaction of IL-1RAcP (red) with the crystal structure of the complex of IL-1L (blue) and IL-1RI (green).
C represents the alternative BACK model of interaction. In B and C the cyan area represents the position of IL-1L residues 73^81.
Table 2
Mutations of IL-1L a¡ecting biological activity but not receptor binding
IL-1L mutation E¡ect on IL-1RI bindinga E¡ect on biological activityb Distance to IL-1RAcPc Ref.
FRONT model BACK model
D54R none (EL4) 32U (LAF) 19 Aî (from D257) 7 Aî (from T274) [26]
K63S none/2^5U (EL4, chondr)d 6000^50 000U (LAF, chondr)d 3 Aî (from F27) 2 Aî (from F27) [27,28]
K65S none/2^5U (EL4, chondr)d 6000^50 000U (LAF, chondr)d 8 Aî (from R10) 4 Aî (from E28) [27,28]
Y121K/A/G/L/T none (EL4) 100^1000U, abolished (LAF, PGE2) 15 Aî (from D272) 7 Aî (from D267) [29]
D145K none (D10) 100U (LAF), abolished (PGE2) 21 Aî (from L6) 3 Aî (from K265) [30,31]
aMuteins of IL-1L were assayed for ability to displace binding of wild type IL-1 from the following IL-1RI-bearing cells : EL4-6.1 (EL4), rabbit
chondrocytes (chondr), D10.G4.1 (D10).
bBiological assays included murine thymocyte proliferation (LAF), activation of rabbit chondrocytes (chondr), production of PGE2 by human
¢broblasts or smooth muscle cells (PGE2).
cCalculated minimal distance between the mutated amino acid and the closest residue of IL-1RAcP (in parentheses) in the two models.
dData refer to the double mutation 63/65 K/K S/S. No data are available for the single mutations.
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for designing targeted inhibitory strategies aimed at blocking
IL-1 pathological activity in severe in£ammatory diseases.
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